Haemonetics annual operating margin
2010
2011
2012
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Haemonetics's operating margin was 11.75% for fiscal 2026.
View full Haemonetics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-28 | 11.75% | −4.55 pp |
| 2025 | 2025-03-29 | 16.30% | +3.70 pp |
| 2024 | 2024-03-30 | 12.60% | −0.76 pp |
| 2023 | 2023-04-01 | 13.35% | +5.22 pp |
| 2022 | 2022-04-02 | 8.13% | −2.18 pp |
| 2021 | 2021-04-03 | 10.31% | −0.15 pp |
| 2020 | 2020-03-28 | 10.46% | +1.82 pp |
| 2019 | 2019-03-30 | 8.63% | +2.42 pp |
| 2018 | 2018-03-31 | 6.21% | +8.40 pp |
| 2017 | 2017-04-01 | −2.19% | −6.64 pp |
| 2015 | 2015-03-28 | 4.45% | −0.49 pp |
| 2014 | 2014-03-29 | 4.95% | −1.38 pp |
| 2013 | 2013-03-30 | 6.33% | −5.87 pp |
| 2012 | 2012-03-31 | 12.19% | −4.14 pp |
| 2011 | 2011-04-02 | 16.34% | +3.43 pp |
| 2010 | 2010-04-03 | 12.90% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-06-27 | 16.93% | +0.17 pp |
| Q4 2026 | 2026-03-28 | −6.65% | −28.23 pp |
| Q3 2026 | 2025-12-27 | 19.88% | +2.95 pp |
| Q2 2026 | 2025-09-27 | 17.87% | +2.91 pp |
| Q1 2026 | 2025-06-28 | 16.76% | +4.94 pp |
| Q4 2025 | 2025-03-29 | 21.58% | +12.86 pp |
| Q3 2025 | 2024-12-28 | 16.94% | +3.26 pp |
| Q2 2025 | 2024-09-28 | 14.96% | +3.87 pp |
| Q1 2025 | 2024-06-29 | 11.83% | −5.41 pp |
| Q4 2024 | 2024-03-30 | 8.72% | −2.86 pp |
| Q3 2024 | 2023-12-30 | 13.67% | −0.50 pp |
| Q2 2024 | 2023-09-30 | 11.10% | −4.61 pp |
| Q1 2024 | 2023-07-01 | 17.24% | +5.47 pp |
| Q4 2023 | 2023-04-01 | 11.58% | +4.34 pp |
| Q3 2023 | 2022-12-31 | 14.18% | +0.45 pp |
| Q2 2023 | 2022-10-01 | 15.71% | +5.49 pp |
| Q1 2023 | 2022-07-02 | 11.77% | +11.16 pp |
| Q4 2022 | 2022-04-02 | 7.24% | +16.65 pp |
| Q3 2022 | 2022-01-01 | 13.72% | −3.09 pp |
| Q2 2022 | 2021-10-02 | 10.22% | −17.84 pp |
| Q1 2022 | 2021-07-03 | 0.61% | −5.38 pp |
| Q4 2021 | 2021-04-03 | −9.41% | −20.31 pp |
| Q3 2021 | 2020-12-26 | 16.82% | +1.02 pp |
| Q2 2021 | 2020-09-26 | 28.06% | +8.37 pp |
| Q1 2021 | 2020-06-27 | 5.99% | +11.57 pp |
| Q4 2020 | 2020-03-28 | 10.90% | +1.34 pp |
| Q3 2020 | 2019-12-28 | 15.80% | +4.35 pp |
| Q2 2020 | 2019-09-28 | 19.69% | +8.90 pp |
| Q1 2020 | 2019-06-29 | −5.58% | −7.89 pp |
| Q4 2019 | 2019-03-30 | 9.57% | +3.46 pp |
| Q3 2019 | 2018-12-29 | 11.45% | +11.02 pp |
| Q2 2019 | 2018-09-29 | 10.79% | +0.03 pp |
| Q1 2019 | 2018-06-30 | 2.31% | −5.57 pp |
| Q4 2018 | 2018-03-31 | 6.11% | — |
| Q3 2018 | 2017-12-30 | 0.43% | — |
| Q2 2018 | 2017-09-30 | 10.76% | — |
| Q1 2018 | 2017-07-01 | 7.87% | — |
Over the last five reported fiscal years, Haemonetics's operating margin increased from 10.31% to 11.75%, a change of +1.44 percentage points. The latest reported quarter, Q1 2027, shows 16.93%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Haemonetics filings at SEC.gov ↗